Cognition Therapeutics Inc (CGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.64-7.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CGTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CGTX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-11-05
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 3, 2026, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on Nasdaq Capital Market pursua…
Why it matters: The 545-person START study tests zervimesine in early Alzheimer's disease. Its results can shape the next trial plan.
Watch forThe company reports START results in 2027 and says the study met its stated main goal.
Also watch forThe company reports that START missed its stated main goal, or the results slip beyond 2027.
Why it matters: The next report can show whether cash use matches the stated runway. A trial update can clarify the next steps after FDA alignment.
Watch forThe November 5 report keeps the cash runway at least through Q4 2027 and gives a clear next step for the DLB Phase 3 trial.
Also watch forThe report cuts the runway to before Q4 2027 or reports a delay to protocol completion or trial start.
Why it matters: The DLB trial and START results need funding. A shorter runway could put pressure on trial plans.
Worry ifA company update cuts the stated cash runway to before Q4 2027.
Less concerning ifA later update keeps or extends the runway through Q4 2027, with cash and grant funds disclosed.
Why it matters: Lower trial work drove much of the recent cost drop. More trial work may raise spending, while further cuts may signal slower study activity.
Watch forQ3 research and development expense rises above $5.1 million. The company links the rise to DLB or START trial work.
Also watch forQ3 research and development expense falls below $5.1 million. The company says trial activity is lower.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$196 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $665 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,697 loss on $10,000 · 67.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: FDA alignment clears key design points. Starting the trial on time would move zervimesine from planning into testing.
Supportive ifThe company starts enrolling patients in the planned DLB Phase 3 trial by mid-2027, using 100 mg daily for nine months.
Worry ifThe protocol is still incomplete. Enrollment has not begun by mid-2027, or the planned dose or trial design changes.